An API portfolio elevated by Verilege™
In the world of pharmaceuticals, managing the intricacies of regulatory compliance, ensuring ingredient quality, and meeting sustainability targets is a complex task.
Our API portfolio is elevated by Verilege™, a distinct suite of expert services and superior customer care that helps simplify the drug approval process. Driven by continuous improvement, Verilege™ helps you achieve and uphold regulatory and quality compliance, progress towards your sustainability goals, and de-risk your supply chain. The Verilege™ program comes in tiered service levels that adapt to your individual needs. This allows you to focus on what really matters - bringing life-changing and life-saving medicines to market.
dsm-firmenich
-
Country/Region:Switzerland
-
On CPHI since:2015
-
Certificates:3
-
Employees:5000+
Other Content from dsm-firmenich (12)
-
News Transforming Pharma Sustainability: dsm-firmenich’s Nature and Climate Strategy
In the following interview, dsm-firmenich shows how they are leading the way in pharmaceutical sustainability by addressing key challenges, aligning with the UN SDGs, and driving innovative solutions to build resilient supply chains and reduce environmental impact.
-
News Press Release: New clinical study validates dsm-firmenich’s CBtru® as a promising pathway for patient-friendly CBD-based therapies
dsm-firmenich, a leading innovator in health, nutrition, and beauty reveals new clinical data confirming that the bioavailability of cannabidiol (CBD)-based therapies can be enhanced in oral solid dosage forms.
-
News Press Release: dsm-firmenich launches novel taste solutions portfolio for pharmaceutical applications
dsm-firmenich launches taste solutions for pharma, enhancing drug palatability and market readiness with expert-backed flavors, maskers, and sensates. -
News CPHI Frankfurt 2022: Innovator Interview – DSM Biomedical
At CPHI Frankfurt we spoke to Anne-Cecile Bayne, Global Science & Innovation Lead Pharma and Medical Nutrition, and Marc Hendriks, Vice President Strategy & Business Development, on their expertise in nitrosamines and business strategy at DSM Biomedical.
-
Whitepaper A comprehensive Taste offering, carefully curated for pharma
Improving the palatability and acceptance of medication to enhance patient compliance and establish clear product differentiation in an increasingly competitive marketplace. -
Brochure dsm-firmenich Pharma Partner Brochure
From high-quality ingredients to regulatory, quality, and sustainability expert services - count on us to help you better the lives of patients worldwide. -
Datasheet CBtru®, a drug delivery solution for oral solid dosage forms
Formulating a highly lipophilic and poorly soluble crystalline molecule, such as cannabidiol (CBD), can be a complex task. In fact, the oral bioavailability of CBD can be as low as 6% in humans, as a result of incomplete absorption in the gut and significant pre-systemic elimination in the liver. This has slowed the development of patient-friendly solid oral dosage forms—until now.CBtru®, an innovative, patent-pending drug delivery solution, is making a new era in drug formulation possible—one that unlocks the true potential of highly lipophilic molecules, like CBD. Enabling optimized bioavailability in solid oral dosage forms is paving the way for more patient-friendly delivery systems, such as tablets and capsules. This will help increase patient convenience and compliance, and elevate patient care worldwide.